Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise

RELEASE DATE
05-Jan-2016
REGION
Global
Research Code: 9A35-00-42-00-00
SKU: LS00029-GL-MR_16870

$450.00

Special Price $337.50 save 25 %

In stock
SKU
LS00029-GL-MR_16870

$450.00

$337.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.

Table of Contents